PreMD to reacquire rights to Prevu skin sterol tests from McNeil

By Lisa Kerner

Charlotte, N.C., Sept. 26 - PreMD Inc. said license, development and supply agreements with McNeil Consumer Healthcare for its Prevu Skin Sterol Test will end in three months, giving PreMD all worldwide rights to the family of skin sterol tests.

McNeil's change in strategic focus led to the termination, according to a news release.

PreMD said it will assess market opportunities, including partnerships for the reacquired Prevu line.

"Our business is in a good financial position to manage this change," PreMD president and chief executive officer of the Toronto predictive medicine company Brent Norton said in the release.

"While we had originally anticipated receiving certain milestone payments from McNeil, which will now not be forthcoming after the three-month transition period, the potential contribution from the commercialization of Prevu could be dramatically improved."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.